Clinical trials are subject to regulation that aims to ensure they are well designed, with risks to participants minimised, and any serious risks communicated clearly to participants. Jonathan Mendel and colleagues assess how well current regulatory frameworks meet these aims using three rheumatoid arthritis trials.